Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation

xlomafota.13 shared this article with you from Inoreader Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation Via Latest Results for Acta Neuropathologica Communications Abstract The molecular chaperone Clusterin (CLU) impacts the amyloid pathway in Alzheimer's disease (AD) but its role in tau pathology is unknown. We observed CLU co-localization with tau aggregates in AD and primary tauopathies and CLU levels were upregulated in response to tau accumulation. To further elucidate the effect of CLU on tau pathology, we utilized a gene delivery approach in CLU knock-out (CLU KO) mice to drive expression of tau bearing the P301L mutation. We found that loss of CLU was associated with exacerbated tau pathology and anxiety-like behaviors in our mouse model of tauopathy. Additionally, we found that CLU dramatically inhibited tau fibrilization using an in vitro assay. Together, these results demonstrate that CLU plays a major role in both amyloid and tau pathologies in AD. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.